Biopharmaceutical Manufacturing is the innovative process of producing therapeutic drugs and pharmaceuticals using living cells and biological systems. This cutting-edge field combines biology, chemistry, and engineering to create complex molecules that serve as the foundation for advanced medical treatments. Unlike traditional pharmaceuticals, biopharmaceuticals are derived from living organisms, such as bacteria, yeast, or mammalian cells, employing genetic engineering and bioprocessing techniques. Biopharmaceutical Manufacturing plays a pivotal role in delivering biologics, monoclonal antibodies, vaccines, and other personalized medicines, contributing significantly to modern healthcare. Its precision, scalability, and focus on quality make it a cornerstone in the development of advanced therapies, ultimately enhancing patient outcomes. This dynamic field continuously evolves, harnessing the power of science and technology to drive medical innovation forward.
In the realm of Biopharmaceutical Manufacturing, several crucial areas shape the landscape of this dynamic field. Here are the primary focus areas within Biopharmaceutical Manufacturing:
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia